Biotechnology major Genentech is planning to increase its research and development spending in 1992 to 50% of revenues, up from the 43% invested in 1991, according to chief executive Kirk Raab. This increase of nearly 20% is aimed at having three new products on the market by 1995.
Before the end of 1992, Genentech is planning both to expand the markets for its existing products, and achieve a number of milestones in the development of its newer drugs.
Results from post-marketing studies of the thrombolytic Activase (tissue plasminogen activator) are expected, and it is hoped that these will, long-term, increase the market for the product. One trial, which has already been completed, investigated the pre-hospital administration of Activase in myocardial infarction patients, while the GUSTO study is looking at early administration after the onset of MI symptoms.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze